COST-EFFECTIVENESS ANALYSIS OF INSULIN DETEMIR VERSUS INSULIN NEUTRAL PROTAMINE HAGEDORN (NPH) IN PATIENTS WITH TYPE 1 DIABETES MELLITUS IN SPAIN

被引：0
|
作者：
Ramirez de Arellano, A. [1 ]
Lizan, L. [2 ]
Prades, M. [2 ]
Morales, C. [3 ]
De Luis, D. [4 ]
机构：
[1] Novo Nordisk Pharma SA, Madrid, Spain
[2] Outcomes 10, Castellon de La Plana, Spain
[3] Hosp Virgen de la Macarena, Seville, Spain
[4] Hosp Rio Hortega, Valladolid, Spain
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB64
引用
收藏
页码：A343 / A343
页数：1
相关论文
共 50 条
  • [31] An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes
    Gupta, Vishal
    Baabbad, Ranya
    Hammerby, Eva
    Nikolajsen, Annie
    Shafie, Asrul Akmal
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (04) : 263 - 272
  • [32] Daily insulin doses and injection frequencies of neutral protamine hagedorn (NPH) insulin, insulin detemir and insulin glargine in type 1 and type 2 diabetes: a multicenter analysis of 51 964 patients from the German/Austrian DPV-wiss database
    Laubner, K.
    Molz, K.
    Kerner, W.
    Karges, W.
    Lang, W.
    Dapp, A.
    Schuett, M.
    Best, F.
    Seufert, J.
    Holl, R. W.
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2014, 30 (05) : 395 - 404
  • [33] A randomised, open-labelstudy of insulin glargine or neutral protamine Hagedorn insulin in Chinese paediatric patients with type 1 diabetes mellitus
    Min Liu
    Zhiguang Zhou
    Jinhua Yan
    Pin Li
    Wenhui Song
    Junfen Fu
    Xiaobo Chen
    Weigang Zhao
    Li Xi
    Xiaoping Luo
    Liang Sha
    Xueyuan Deng
    Chunxiu Gong
    BMC Endocrine Disorders, 16
  • [34] A randomised, open-labelstudy of insulin glargine or neutral protamine Hagedorn insulin in Chinese paediatric patients with type 1 diabetes mellitus
    Liu, Min
    Zhou, Zhiguang
    Yan, Jinhua
    Li, Pin
    Song, Wenhui
    Fu, Junfen
    Chen, Xiaobo
    Zhao, Weigang
    Xi, Li
    Luo, Xiaoping
    Sha, Liang
    Deng, Xueyuan
    Gong, Chunxiu
    BMC ENDOCRINE DISORDERS, 2016, 16 : 67
  • [35] CLINICAL AND COST OUTCOMES OF TREATMENT WITH INSULIN GLARGINE VERSUS INSULIN DETEMIR IN INSULIN NAIVE TYPE 2 DIABETES PATIENTS: COST-EFFECTIVENESS ANALYSIS IN THE KAZAKHSTAN SETTING
    Kostyuk, A.
    Akanov, A.
    Almadiyeva, A.
    VALUE IN HEALTH, 2016, 19 (03) : A203 - A204
  • [36] THE IMPACT OF INSULIN DETEMIR COMPARED TO NEUTRAL PROTAMINE HAGEDORN INSULIN ON LONG-TERM DIABETES-RELATED COMPLICATIONS: A MODELING ANALYSIS IN TYPE 1 DIABETES PATIENTS IN BELGIUM, FRANCE, GERMANY, ITALY AND SPAIN
    Gschwend, M. H.
    Aagren, M.
    Valentine, W. J.
    VALUE IN HEALTH, 2008, 11 (06) : A495 - A495
  • [37] Long-term clinical outcomes of insulin detemir versus NPH for type 1 diabetes patients in Spain
    Kotchie, R.
    Aagren, M.
    Nielsen, S.
    Valentine, W. J.
    Goodall, G.
    VALUE IN HEALTH, 2007, 10 (06) : A273 - A273
  • [38] Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK
    McEwan, Phil
    Poole, Chris D.
    Tetlow, Tony
    Holmes, Paul
    Currie, Craig J.
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 : S21 - S31
  • [39] Effects of QD insulin detemir or neutral protamine hagedorn on blood glucose control in patients with type 1 diabetes mellitus using a basal-bolus regimen
    Russell-Jones, D
    Simpson, R
    Hylleberg, B
    Draeger, E
    Bolinder, J
    CLINICAL THERAPEUTICS, 2004, 26 (05) : 724 - 736
  • [40] Comparison of Inpatient Insulin Regimens with Detemir plus Aspart Versus Neutral Protamine Hagedorn plus Regular in Medical Patients with Type 2 Diabetes
    Umpierrez, Guillermo E.
    Hor, Tiffany
    Smiley, Dawn
    Temponi, Angel
    Umpierrez, Denise
    Ceron, Miguel
    Munoz, Christina
    Newton, Christopher
    Peng, Limin
    Baldwin, David
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (02): : 564 - 569
12345